AgomAb

Drug Discovery · Antwerp, Belgium · Founded 2017 · Privately Held (backing)

Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. AgomAb is based in Antwerp, Belgium and was founded in 2017. Its last known valuation is $416 million. It has raised $334 million across 1 recorded round; the latest was a $101 million Series C in Oct 2023.

Last price · $/share
—
Implied valuation
$415.6M
Total raised
$334.0M
Last round
Later Stage VC (Series C)
Oct 2023
How much has AgomAb raised?
$334.0Macross 1 recorded rounds · Oct 2023 – Oct 2023

Most recently, AgomAb raised $100.7M in its Later Stage VC (Series C) (Oct 2023).

Free account
More of AgomAb with a free account
  • ·The complete investor list: 17 names
  • ·Watch AgomAb: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

AgomAb round by round

1 rounds
Oct 2023Later Stage VC (Series C)$100.7M▮
+ 1 more investors · free account

How much has AgomAb raised?

AgomAb has raised $334 million in total; 1 of its rounds is on record. The largest on record was a $101 million Series C in Oct 2023.

AgomAb investors

17 investors are on record for AgomAb, including Fidelity Management & Research Company, Canaan Partners, The Invus Group and Cormorant Asset Management. By type, the record holds 4 venture capital firms, 4 private equity firms and 1 hedge fund. The Series C in Oct 2023 drew 3 investors.

For fundraisers
Raising for a company like AgomAb?

17 investors have backed AgomAb — start your target list with the firms already writing checks in drug discovery.

See all 17 investors →

Frequently asked about AgomAb

How much has AgomAb raised?
AgomAb has raised $334.0M in total across 1 recorded funding rounds.
When was AgomAb's last funding round?
AgomAb's most recent recorded round was Later Stage VC (Series C) in Oct 2023, raising $100.7M.